-
Tytuł:
-
A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study.
-
Autorzy:
-
Zheng S; Department of Oncology, Hangzhou First People's Hospital, Hangzhou Cancer Hospital, Zhejiang University School of Medicine Affiliated Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, 310006, China. .
Zhou Y; Department of Oncology, Hangzhou First People's Hospital, Hangzhou Cancer Hospital, Zhejiang University School of Medicine Affiliated Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, 310006, China.
Sun Y; Department of Oncology, Hangzhou First People's Hospital, Hangzhou Cancer Hospital, Zhejiang University School of Medicine Affiliated Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, 310006, China.
Wang Z; Department of Oncology, Hangzhou First People's Hospital, Hangzhou Cancer Hospital, Zhejiang University School of Medicine Affiliated Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, 310006, China.
Lu Y; Department of Oncology, Hangzhou First People's Hospital, Hangzhou Cancer Hospital, Zhejiang University School of Medicine Affiliated Hangzhou First People's Hospital, Nanjing Medical University Affiliated Hangzhou Hospital, Zhejiang Chinese Medical University Affiliated Hangzhou First Hospital, Hangzhou, 310006, China.
-
Źródło:
-
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Oct; Vol. 84 (4), pp. 819-827. Date of Electronic Publication: 2019 Aug 06.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Berlin : Springer Verlag
Original Publication: Berlin, New York, Springer International.
-
MeSH Terms:
-
Antineoplastic Combined Chemotherapy Protocols*/administration & dosage
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Capecitabine*/administration & dosage
Capecitabine*/adverse effects
Oxaloacetates*/administration & dosage
Oxaloacetates*/adverse effects
Oxonic Acid*/administration & dosage
Oxonic Acid*/adverse effects
Tegafur*/administration & dosage
Tegafur*/adverse effects
Gastrectomy/*methods
Stomach Neoplasms/*drug therapy
Chemotherapy, Adjuvant/methods ; China/epidemiology ; Cohort Studies ; Disease-Free Survival ; Drug Combinations ; Female ; Hand-Foot Syndrome/epidemiology ; Hand-Foot Syndrome/etiology ; Humans ; Incidence ; Male ; Middle Aged ; Outcome and Process Assessment, Health Care ; Paraneoplastic Polyneuropathy/epidemiology ; Paraneoplastic Polyneuropathy/etiology ; Stomach Neoplasms/pathology ; Stomach Neoplasms/surgery
-
Contributed Indexing:
-
Keywords: Adjuvant chemotherapy; Combined therapy; D2 resection; Gastric cancer; Monotherapy
-
Substance Nomenclature:
-
0 (Drug Combinations)
0 (Oxaloacetates)
150863-82-4 (S 1 (combination))
1548R74NSZ (Tegafur)
5VT6420TIG (Oxonic Acid)
6804DJ8Z9U (Capecitabine)
-
SCR Protocol:
-
XELOX
-
Entry Date(s):
-
Date Created: 20190808 Date Completed: 20200512 Latest Revision: 20200512
-
Update Code:
-
20240105
-
DOI:
-
10.1007/s00280-019-03911-5
-
PMID:
-
31388724
-
Objective: Currently, radical surgery with D2 lymphadenectomy has become the standard operation mode of patients in East Asian countries who suffer from resectable gastric cancer. Our target is to compare the efficacy of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection.
Methods: We selected 186 patients with gastric cancer who underwent D2 resection in Hangzhou First People's Hospital and Hangzhou Cancer Hospital from June 2014 to June 2017. All patients were followed up for more than 3 years. The primary endpoint was disease-free survival (DFS), and the secondary endpoints were overall survival (OS) and toxicity.
Results: The 3-year DFS of monotherapy group and combined group were, respectively, 50.7% and 64.0%, while the 3-year OS were, respectively, 62.7% and 71.2%. The 3-year DFS and OS of the combined group were higher than the monotherapy group, but the differences had no statistical significance (3-year DFS: P = 0.071; 3-year OS: P = 0.224). Subgroup analysis showed that the DFS of patients with stage III gastric cancer in monotherapy group was significantly lower than the combined group, with the difference that had statistical significance (P = 0.030), while there was no significant difference in OS (P = 0.186). Most toxic and side effects seen in both groups had no significant differences, while the incidence of hand-foot syndrome and peripheral neurotoxicity in combined group was significantly higher than that in the monotherapy group (P < 0.001).
Conclusion: For patients with advanced gastric cancer who underwent D2 resection, compared with S-1 regimen, there is prolonged disease-free survival trend with SOX/XELOX regimen, while there is no significant overall survival benefit.
